SCHEMBL6715751

SCHEMBL6715751

Cc1cccc(NC(=O)C(NC(=S)Nc2ccccc2C(F)(F)F)c2ccccc2)c1C

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.52
ALOX12 P18054 5/20 0.52
ULK1 O75385 1/20 0.48
MAPT P10636 3/20 0.47
NPSR1 Q6W5P4 2/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
PLA2G1B P04054 1/20 0.47
ATG4B Q9Y4P1 1/20 0.47
HPGD P15428 2/20 0.47
LMNA P02545 1/20 0.47
TP53 P04637 1/20 0.46
POLB P06746 2/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
CRHBP P24387 1/20 0.45
NPBWR1 P48145 1/20 0.45
CRHR2 Q13324 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6715497 0.92 ALDH1A1 (0.55) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6716815 0.90 ALDH1A1 (0.53) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6714000 0.85 ALDH1A1 (0.57) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6717555 0.84 ALDH1A1 (0.53) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6717041 0.84 ALOX12 (0.52) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL8346900 0.84 ALDH1A1 (0.48) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL8347960 0.84 ALDH1A1 (0.48) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6714152 0.84 ULK1 (0.53) ALDH1A1ALOX12ULK1MAPTCYP1A2
SCHEMBL6717393 0.83 ALDH1A1 (0.52) ALDH1A1ALOX12ULK1MAPTNPSR1
SCHEMBL6714029 0.83 ALDH1A1 (0.52) ALDH1A1ALOX12ULK1MAPTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors NPS ALLELIX CORPORATION (CA) 2004-08-05 US disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed
WO-2004022534-A1 ARYLGLYCINE DERIVATIVES FOR USE AS GLYCINE TRANSPORT INHIBITORS NPS ALLELIX CORP. (CA) 2004-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040152740-A1 Arylglycine derivatives for use as glycine transport inhibitors SLC1A2, SLC6A7, SLC1A1 ALDH1A1 572/4885ALOX12 2690/4885ULK1 3906/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.